Advanced Hepatocellular Carcinoma Clinical Trial
Official title:
Single-arm, Prospective Clinical Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma With High Tumor Load
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
At present, there are no prospective clinical studies using the combination regimen (TAE+HAIC+ Apatinib + camrelizumab) in the treatment of advanced liver cancer. Therefore, in this study, investigators designed a single-arm, prospective, multicenter, phase Ⅱ clinical study of arterial infusion of TAE+HAIC+ Apatinib + camrelizumab in the treatment of advanced liver cancer with high tumor load, to explore the safety and efficacy of this regimen. If study gets positive results, it will provide a reference for the subsequent phase Ⅲ clinical trial design, which is expected to provide a new effective approach for the treatment of advanced liver cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT05057845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02638857 -
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02632006 -
Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00752063 -
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00517920 -
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Recruiting |
NCT05797805 -
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05070156 -
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma
|
Early Phase 1 | |
| Not yet recruiting |
NCT06092112 -
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT01214343 -
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
|
Phase 3 | |
| Completed |
NCT00999882 -
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
|
Phase 1 | |
| Withdrawn |
NCT00756782 -
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00534664 -
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04503902 -
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04777708 -
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
|
Early Phase 1 | |
| Completed |
NCT04072679 -
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Suspended |
NCT04066660 -
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
|
N/A | |
| Withdrawn |
NCT05592197 -
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
|
N/A | |
| Completed |
NCT02528643 -
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 |